Affinity and avidity in antibody-based tumor targeting

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 2, 2009, Pages 155-161

  Rudnick, Stephen I ^a   Adams, Gregory P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Affinity; Antibody; Avidity; Internalization; ScFv; Specificity; Tumor targeting

Indexed keywords

MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; EXPERIMENTAL STUDY; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; MICE; NEOPLASMS;

EID: 66249109940     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0627     Document Type: Article

References (48)

1. Weiner LM. Fully human therapeutic monoclonal anti- bodies. J Immunother 2006; 29: 1.
2. Loo L, Robinson MK, Adams GP Antibody engineering principles and applications. Cancer J 2008; 14: 149.
3. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109: 170. (Pubitemid 46106231)
4. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147. (Pubitemid 41486396)
5. Russeva MG, Adams GP. Radioimmunotherapy with en- gineered antibodies. Expert Opin Biol Ther 2004; 4: 217.
6. Zafir-Lavie I, Michaeli Y, Reiter Y. Novel antibodies as an- ticancer agents. Oncogene 2007; 26: 3714.
7. Mayer A, Chester KA, Flynn AA, Begent RH. Taking en- gineered anti-CEA antibodies to the clinic. J Immunol Method 1999; 231 (1-2) : 261. (Pubitemid 30394739)
8. Robinson MK, Weiner LM, Adams GP. Improving mono- clonal antibodies for cancer therapy. Drug Dev Res 2004; 61: 172. (Pubitemid 39043721)
9. Covell DG, Barbet J, Holton OD, et al. Pharmacokinetics of monoclonal immunoglobulin G1, F (ab') 2, and Fab' in mice. Cancer Res 1986; 46: 3969.
10. Thurber GM, Zajic SC, Wittrup KD. Theoretic [sic] criteria for antibody penetration into solid tumors and micro- metastases. J Nucl Med 2007; 48: 995. (Pubitemid 46909929)
11. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50 (3suppl) : 814s.
12. Jain RK, Baxter LT. Mechanisms of heterogeneous distribu- tion of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 1988; 48 (24ptl) : 7022. (Pubitemid 19013976)
13. Zhang Y, Pastan I. High shed antigen levels within tumors: An additional barrier to immunoconjugate therapy. Clin Cancer Res 2008; 14: 7981.
14. Baker JH, Lindquist KE, Huxham LA, et al. Direct visuali- zation of heterogeneous extravascular distribution of tras- tuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 2008; 14: 2171.
15. Fujimori K, Covell, DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of im- munoglobulin G, F (ab') 2, and Fab in tumors. Cancer Res 1989; 49: 5656. (Pubitemid 19256448)
16. Fujimori K, Covell, DG, Fletcher JE, Weinstein JN. A mod- eling analysis of monoclonal antibody percolation through tumors: A binding-site barrier. J Nucl Med 1990; 31: 1191. (Pubitemid 20213280)
17. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier. Cancer Res 1992; 52: 5144.
18. van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a "binding site barrier." Cancer Res 1991; 51: 4776.
19. Weinstein JN, van Osdol W. The macroscopic and micro- scopic pharmacology of monoclonal antibodies. Int J Im- munopharmacol 1992; 14: 457.
20. Saga T, Neumann RD, Heya T, et al. Targeting cancer mi- crometastases with monoclonal antibodies: A binding-site barrier. Proc Natl Acad Sci U S A 1995; 92: 8999.
21. Kievit, E, Pinedo HM, Schlüper HM, et al. Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmuno- therapy in human ovarian cancer xenografts. Br J Cancer 1996; 73: 457. (Pubitemid 26056466)
22. Schier R, Bye J, Apell G, et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol 1996; 255: 28. (Pubitemid 26104182)
23. Schier R, McCall A, Adams GP, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263: 551. (Pubitemid 26382075)
24. Adams, GP, Schier R, Marshall K, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998; 58: 485. (Pubitemid 28087411)
25. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750. (Pubitemid 32691886)
26. Tang Y, Lou J, Alpaugh RK, et al. Regulation of antibody- dependent cellular cytotoxicity by IgG intrinsic and appar- ent affinity for target antigen. J Immunol 2007; 179: 2815.
27. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: Transport opposed by systemic and antigen- mediated clearance. Adv Drug Deliv Rev 2008; 60: 1421.
28. Ackerman ME, Pawlowski D, Wittrup KD. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther 2008; 7: 2233.
29. Zuckier LS, Berkowitz EZ, Sattenberg RJ, et al. Influence of affinity and antigen density on antibody localization in a mod- ifiable tumor targeting model. Cancer Res 2000; 60: 7008. (Pubitemid 32059177)
30. Lammerts van Bueren, JJ, Bleeker WK, Bogh HO, et al. Effect of target dynamics on pharmacokinetics of a novel thera- peutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action. Cancer Res 2006; 66: 7630. (Pubitemid 44289220)
31. Austin CD, DeMazière AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer thera- peutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15: 5268. (Pubitemid 39564723)
32. Kyriakos RJ, Shih LB, Ong GL, et al. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992; 52: 835.
33. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti- carcinoembryonic antigen antibody internalization: Effects of affinity, bivalency, and stability. Cancer Immunol Im- munother 2008; 57: 1879.
34. Neve RM, Nielsen UB, Kirpotin DB, et al. Biological effects of anti-ErbB2 single chain antibodies selected for internal- izing function. Biochem Biophys Res Commun 2001; 280: 274. (Pubitemid 32917507)
35. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: Dis- tribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem 2003; 278: 23343. (Pubitemid 36830149)
36. Thurber GM, Wittrup KD. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic con- sumption in tumor spheroids. Cancer Res 2008; 68: 3334.
37. Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2- positive tumor xenografts with an iodine-124 labeled anti- HER2 diabody. Cancer Res 2005; 65: 1471. (Pubitemid 40270176)
38. Deyev SM, Lebedenko EN. Multivalency: The hallmark of antibodies used for optimization of tumor targeting by de- sign. Bioessays 2008; 30: 904.
39. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126. (Pubitemid 41486394)
40. Hudson PJ, Kortt AA. High avidity scFv multimers: Dia- bodies and triabodies. J Immunol Method 1999; 231 (1-2) : 177. (Pubitemid 30394733)
41. Todorovska A, Dolezal O, Kortt AA, et al. Design and ap- plication of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Method 2001; 248 (1-2) : 47. (Pubitemid 32167024)
42. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extra- cellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405. (Pubitemid 28190739)
43. Nielsen UB, Adams GP, Weiner LM, et al. Targeting of bi- valent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res 2000; 60: 6434.
44. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006; 12: 1599.
45. Kubetzko S, Balic E, Waibel R, et al. PEGylation and mul- timerization of the anti-p185HER-2 single chain Fv fragment 4D5: Effects on tumor targeting. J Biol Chem 2006; 281: 35186. (Pubitemid 46043248)
46. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimunotherapy with bispecific anti- bodies. Mol Cancer Ther 2002; 1: 553.
47. Kipriyanov SM, Le Gall F. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Devel 2004; 7: 233. (Pubitemid 44111956)
48. Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances tar- geting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99: 1415.